skip to Main Content

Welcome

Celebrating 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

ADVOCACY UPDATES

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

12/01/21: Research Grant Cycle
Learn more

04/01/22: Fellow Exam Application Deadline
Learn more

06/01/22: Research Grant Cycle
Learn more

06/26/22: Membership Application Deadline to be eligible for AAOA Member rate for the 2022 Basic Course

08/01/22: Scientific Abstract Submission Deadline

09/01/22: Membership Application Deadline to be voted in at the 2022 Annual Meeting

EDUCATION

The education committee of the AAOA has put together an all-star lineup for this year’s virtual Annual Meeting taking place October 16th to 21st. Like last year, our Annual Meeting will offer live-stream and on-demand content. Some content will be available for self-paced on-demand viewing on September 15th, 2021. Learn More

IFAR

Available Now

IFAR Impact Factor: 2.454

aaoaf-ifar

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2021 AAOA Annual Meeting
Pre-launch Mid-September
Live Stream Starting on Oct 16 | Virtual
Learn More and Register

2022 AAOA Advanced Course
In-Person!!! Santa Fe, NM
January 13-15, 2022
Learn More and Register

2022 AAOA Basic Course
The Diptomat Beach Resort, Hollywood, FL
June 30-July 2, 2022

USP 797 Online Module
Learn More and Register

News and Updates

Revised CPT Code for 2020

The following revisions and additions to Current Procedural Terminology (CPT ® American Medical Association) codes related…

read more

The MIPS Update from the Centers for Medicare and Medicaid Services

The MIPS 2019 Data Submission Period is Now Open MIPS Eligible Clinicians Can Start Submitting…

read more
College Allergy Symptoms Treatment Back to Shcool

PRACTICE RESOURCES

AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More

PARTNER RESOURCE CENTER

AAOA has launched a Partner Resource Center to bring you partner resources that can assist your practice and patient care.

Visit the New Center>

PATIENT CORNER

AAOA Logo

Practice Resources

New Requirements for Biological Testing

bee-2289227_640

Venom and Biological Testing Update 2013

Effective January 1, 2013, new codes have been established to report allergy testing for venoms, drugs and biological.  Previously, Code 95010 was used to report percutaneous testing (scratch, puncture, prick) sequential and incremental and Code 95015 was used to report Intracutaneous testing (intradermal).  It was found that in most cases, both codes were reported for a single patient since both percutaneous and intracutaneous testing was typically performed.  These codes have now been deleted and replaced by two new codes, 95017 and 95018.

Code 95017 is defined as allergy testing, any combination of percutaneous (scratch, puncture, prick) and intracutaneous (intradermal) sequential and incremental, with venoms, immediate test reaction, including test interpretation and report, specify number of tests.  Code 95018 has the identical definition but is specified for testing drugs and biologicals; i.e., allergy testing, any combination of percutaneous (scratch, puncture, prick) and intracutaneous (intradermal) sequential and incremental, with drugs or biologicals, immediate test reaction, including test interpretation and report, specify number of tests.  Thus, the distinction between these codes is no longer based on the technique used but rather whether venoms or drugs/biologicals are being tested.

A Member Benefit

Allergy & Rhinology Journal (IFAR)

The International Forum of Allergy & Rhinology (IFAR) is the official journal of the AAOA and the American Rhinologic Society (ARS). Published monthly by John Wiley & Sons, Inc., IFAR provides a forum for clinical researchers, basic scientists, clinicians, and others to publish original research and explore controversies in the medical and surgical treatment of patients with otolaryngic allergy, rhinologic, and skull base conditions.

Read Articles

pollen-543490_640
Back To Top